KOL Pulse AI· @KolPulseAI · X·· 1 天前评分70
正文 · 原文
"It hard to explain why 1 trial with gem/cis +/-PD(L)1 (NIAGARA) is +ve for EFS/OS and 2 very similar trials (presented today) are negative in MIBC." @tompowles1
#ESMO26 ENERGIZE + KEYNOTE-866 slides and physician debate: https://hubs.ly/Q04CdhpY0
@bmsnews @Merck @AstraZeneca
41 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
4735O按 Proffered paper 1: Genitourinary tumour, renal and urothelial 对上
Perioperative pembrolizumab (pembro) or placebo (pbo) + neoadjuvant cisplatin (cis) and gemcitabine (gem) in participants (pts) with muscle-invasive bladder cancer (MIBC): the double-blind, phase 3 KEYNOTE-866 study
https://esmocongress.esmo.org来源：KOL Pulse AI · x.com